Molecular Upstaging of Sentinel Lymph Nodes in Melanoma: Where Are We Now?

Steve R. Martinez, Takuji Mori, Dave S B Hoon

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The presence of lymph node metastasis is the best predictor of disease progression and overall survival in patients who have melanoma. Lymphatic mapping and selective lymphadenectomy allows directed pathologic analysis of the node or nodes most likely to have metastatic disease. To diagnose metastatic disease in SLNs reliably requires a coordinated effort by nuclear medicine physicians, surgeons, and pathologists. Errors may occur if quality assurance is not emphasized at any point during the process. This, along with the presence of occult metastatic disease, may lead to disease recurrence and progression, even when SLN histologically are free of disease. Molecular upstaging of occult malignant disease has the potential to provide important information to facilitate the diagnosis, surveillance, and treatment of cancer. The detection of occult tumor cells in SLNs and blood provides a powerful tool for assessing early regional and systemic disease spread in patients who have AJCC stage II and III-not only melanoma but also other solid tumors. The use of varying panels of markers from different laboratories has hampered the interpretation of data and made it difficult to unravel the merits of molecular upstaging. Molecular approaches have made a major impact on the field of infectious disease and should one day be of equal usefulness in the diagnosis of cancer.

Original languageEnglish (US)
Pages (from-to)331-340
Number of pages10
JournalSurgical Oncology Clinics of North America
Volume15
Issue number2
DOIs
StatePublished - Apr 2006
Externally publishedYes

Fingerprint

Melanoma
Disease Progression
Neoplasms
Nuclear Medicine
Lymph Node Excision
Communicable Diseases
Sentinel Lymph Node
Biomarkers
Lymph Nodes
Neoplasm Metastasis
Physicians
Recurrence
Survival
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Surgery

Cite this

Molecular Upstaging of Sentinel Lymph Nodes in Melanoma : Where Are We Now? / Martinez, Steve R.; Mori, Takuji; Hoon, Dave S B.

In: Surgical Oncology Clinics of North America, Vol. 15, No. 2, 04.2006, p. 331-340.

Research output: Contribution to journalArticle

Martinez, Steve R. ; Mori, Takuji ; Hoon, Dave S B. / Molecular Upstaging of Sentinel Lymph Nodes in Melanoma : Where Are We Now?. In: Surgical Oncology Clinics of North America. 2006 ; Vol. 15, No. 2. pp. 331-340.
@article{532c287d36614ef79aa6b1d3a5ffedfa,
title = "Molecular Upstaging of Sentinel Lymph Nodes in Melanoma: Where Are We Now?",
abstract = "The presence of lymph node metastasis is the best predictor of disease progression and overall survival in patients who have melanoma. Lymphatic mapping and selective lymphadenectomy allows directed pathologic analysis of the node or nodes most likely to have metastatic disease. To diagnose metastatic disease in SLNs reliably requires a coordinated effort by nuclear medicine physicians, surgeons, and pathologists. Errors may occur if quality assurance is not emphasized at any point during the process. This, along with the presence of occult metastatic disease, may lead to disease recurrence and progression, even when SLN histologically are free of disease. Molecular upstaging of occult malignant disease has the potential to provide important information to facilitate the diagnosis, surveillance, and treatment of cancer. The detection of occult tumor cells in SLNs and blood provides a powerful tool for assessing early regional and systemic disease spread in patients who have AJCC stage II and III-not only melanoma but also other solid tumors. The use of varying panels of markers from different laboratories has hampered the interpretation of data and made it difficult to unravel the merits of molecular upstaging. Molecular approaches have made a major impact on the field of infectious disease and should one day be of equal usefulness in the diagnosis of cancer.",
author = "Martinez, {Steve R.} and Takuji Mori and Hoon, {Dave S B}",
year = "2006",
month = "4",
doi = "10.1016/j.soc.2005.12.012",
language = "English (US)",
volume = "15",
pages = "331--340",
journal = "Surgical Oncology Clinics of North America",
issn = "1055-3207",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Molecular Upstaging of Sentinel Lymph Nodes in Melanoma

T2 - Where Are We Now?

AU - Martinez, Steve R.

AU - Mori, Takuji

AU - Hoon, Dave S B

PY - 2006/4

Y1 - 2006/4

N2 - The presence of lymph node metastasis is the best predictor of disease progression and overall survival in patients who have melanoma. Lymphatic mapping and selective lymphadenectomy allows directed pathologic analysis of the node or nodes most likely to have metastatic disease. To diagnose metastatic disease in SLNs reliably requires a coordinated effort by nuclear medicine physicians, surgeons, and pathologists. Errors may occur if quality assurance is not emphasized at any point during the process. This, along with the presence of occult metastatic disease, may lead to disease recurrence and progression, even when SLN histologically are free of disease. Molecular upstaging of occult malignant disease has the potential to provide important information to facilitate the diagnosis, surveillance, and treatment of cancer. The detection of occult tumor cells in SLNs and blood provides a powerful tool for assessing early regional and systemic disease spread in patients who have AJCC stage II and III-not only melanoma but also other solid tumors. The use of varying panels of markers from different laboratories has hampered the interpretation of data and made it difficult to unravel the merits of molecular upstaging. Molecular approaches have made a major impact on the field of infectious disease and should one day be of equal usefulness in the diagnosis of cancer.

AB - The presence of lymph node metastasis is the best predictor of disease progression and overall survival in patients who have melanoma. Lymphatic mapping and selective lymphadenectomy allows directed pathologic analysis of the node or nodes most likely to have metastatic disease. To diagnose metastatic disease in SLNs reliably requires a coordinated effort by nuclear medicine physicians, surgeons, and pathologists. Errors may occur if quality assurance is not emphasized at any point during the process. This, along with the presence of occult metastatic disease, may lead to disease recurrence and progression, even when SLN histologically are free of disease. Molecular upstaging of occult malignant disease has the potential to provide important information to facilitate the diagnosis, surveillance, and treatment of cancer. The detection of occult tumor cells in SLNs and blood provides a powerful tool for assessing early regional and systemic disease spread in patients who have AJCC stage II and III-not only melanoma but also other solid tumors. The use of varying panels of markers from different laboratories has hampered the interpretation of data and made it difficult to unravel the merits of molecular upstaging. Molecular approaches have made a major impact on the field of infectious disease and should one day be of equal usefulness in the diagnosis of cancer.

UR - http://www.scopus.com/inward/record.url?scp=33646053158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646053158&partnerID=8YFLogxK

U2 - 10.1016/j.soc.2005.12.012

DO - 10.1016/j.soc.2005.12.012

M3 - Article

C2 - 16632218

AN - SCOPUS:33646053158

VL - 15

SP - 331

EP - 340

JO - Surgical Oncology Clinics of North America

JF - Surgical Oncology Clinics of North America

SN - 1055-3207

IS - 2

ER -